Exclusive: How Sequencing Firm ReadCoor Came to be Acquired by 10x Genomics

Last week, ReadCoor, a Boston company that developed an In Situ sequencing technology, was acquired by10x Genomics for $350 million. ReadCoor was backed by Decheng Capital, a Shanghai-Silicon Valley venture firm. From their first meeting, Decheng was impressed with ReadCoor's technology, which measures large numbers of molecules directly in tissue while preserving the precise location of the molecules in the tissue -- the new field of spatial-omics. In an exclusive interview, the company told ChinaBio® Today about ReadCoor's revolutionary technology and its significance for functional genomics, drug development and the understanding of disease. More details... Stock Symbol: (NSDQ: TXG) Share this with colleagues: // //